DBV Technologies S.A. (DBVT): Total Assets
$233.72M
As of 2025-12-31
$223.20M
As of 2026-06-30
-1.8%
3-year compound annual growth
-3.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $233.72M | +256.0% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $65.66M | -64.1% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $182.99M | -25.8% | 2025-04-11, Balance as of period end |
| 2022-12-31 | $246.52M | +68.0% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $146.72M | -46.1% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $272.25M | +0.2% | 2022-03-09, Balance as of period end |
| 2019-12-31 | $271.73M | n/a | 2021-03-17, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $233.72M | +256.0% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $1.53M | -7.1% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $318.94M | -27.6% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $342.73M | +15.2% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $43.52M | -47.2% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $791.59M | +4.9% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $2.27B | +1.0% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $98.73M | +103.7% |
| Curis Inc (CRIS) | 2025-12-31 | $19.97M | -51.6% |
Compare DBVT, ZEOX, FATE, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗